Literature DB >> 16586533

Helicobacter pylori eradication to prevent gastric cancer: underlying molecular and cellular mechanisms.

Shingo Tsuji1, Masahiko Tsujii, Hiroaki Murata, Tsutomu Nishida, Masato Komori, Masakazu Yasumaru, Shuji Ishii, Yoshiaki Sasayama, Sunao Kawano, Norio Hayashi.   

Abstract

Numerous cellular and molecular events have been described in development of gastric cancer. In this article, we overviewed roles of Helicobacter pylori (H pylori) infection on some of the important events in gastric carcinogenesis and discussed whether these cellular and molecular events are reversible after cure of the infection. There are several bacterial components affecting gastric epithelial kinetics and promotion of gastric carcinogenesis. The bacterium also increases risks of genetic instability and mutations due to NO and other reactive oxygen species. Epigenetic silencing of tumor suppressor genes such as RUNX3 may alter the frequency of phenotype change of gastric glands to those with intestinal metaplasia. Host factors such as increased expression of growth factors, cytokines and COX-2 have been also reported in non-cancerous tissue in H pylori-positive subjects. It is noteworthy that most of the above phenomena are reversed after the cure of the infection. However, some of them including overexpression of COX-2 continue to exist and may increase risks for carcinogenesis in metaplastic or dysplastic mucosa even after successful H pylori eradication. Thus, H pylori eradication may not completely abolish the risk for gastric carcinogenesis. Efficiency of the cure of the infection in suppressing gastric cancer depends on the timing and the target population, and warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16586533      PMCID: PMC4124339          DOI: 10.3748/wjg.v12.i11.1671

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  141 in total

1.  The role of interleukin-1 polymorphisms in the pathogenesis of gastric cancer.

Authors:  E M El-Omar; M Carrington; W H Chow; K E McColl; J H Bream; H A Young; J Herrera; J Lissowska; C C Yuan; N Rothman; G Lanyon; M Martin; J F Fraumeni; C S Rabkin
Journal:  Nature       Date:  2001-07-05       Impact factor: 49.962

2.  Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis.

Authors:  Yoshimi Kakiuchi; Shingo Tsuji; Masahiko Tsujii; Hiroaki Murata; Naoki Kawai; Masakazu Yasumaru; Arata Kimura; Masato Komori; Takanobu Irie; Eiji Miyoshi; Yutaka Sasaki; Norio Hayashi; Sunao Kawano; Masatsugu Hori
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

3.  Localisation of cyclooxygenase 1 and cyclooxygenase 2 in Helicobacter pylori related gastritis and gastric ulcer tissues in humans.

Authors:  A Tatsuguchi; C Sakamoto; K Wada; T Akamatsu; T Tsukui; K Miyake; S Futagami; T Kishida; Y Fukuda; N Yamanaka; M Kobayashi
Journal:  Gut       Date:  2000-06       Impact factor: 23.059

4.  Genetic instability in intestinal metaplasia is a frequent event leading to well-differentiated early adenocarcinoma of the stomach.

Authors:  K Kobayashi; T Okamoto; S Takayama; M Akiyama; T Ohno; H Yamada
Journal:  Eur J Cancer       Date:  2000-06       Impact factor: 9.162

5.  Interleukin-1beta induces cyclo-oxygenase-2 expression in gastric cancer cells by the p38 and p44/42 mitogen-activated protein kinase signaling pathways.

Authors:  X M Fan; B C Wong; M C Lin; C H Cho; W P Wang; H F Kung; S K Lam
Journal:  J Gastroenterol Hepatol       Date:  2001-10       Impact factor: 4.029

6.  Helicobacter pylori infection and the development of gastric cancer.

Authors:  N Uemura; S Okamoto; S Yamamoto; N Matsumura; S Yamaguchi; M Yamakido; K Taniyama; N Sasaki; R J Schlemper
Journal:  N Engl J Med       Date:  2001-09-13       Impact factor: 91.245

7.  Alterations of telomerase activity and terminal restriction fragment in gastric cancer and its premalignant lesions.

Authors:  S M Yang; D C Fang; Y H Luo; R Lu; P D Battle; W W Liu
Journal:  J Gastroenterol Hepatol       Date:  2001-08       Impact factor: 4.029

8.  Somatic mutations in the DNA damage-response genes ATR and CHK1 in sporadic stomach tumors with microsatellite instability.

Authors:  A Menoyo; H Alazzouzi; E Espín; M Armengol; H Yamamoto; S Schwartz
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

9.  A pilot study investigating the role of NAT1 and NAT2 polymorphisms in gastric adenocarcinoma.

Authors:  R J Boissy; M A Watson; D M Umbach; M Deakin; J Elder; R C Strange; D A Bell
Journal:  Int J Cancer       Date:  2000-08-15       Impact factor: 7.396

10.  Interleukin 1B and interleukin 1RN polymorphisms are associated with increased risk of gastric carcinoma.

Authors:  J C Machado; P Pharoah; S Sousa; R Carvalho; C Oliveira; C Figueiredo; A Amorim; R Seruca; C Caldas; F Carneiro; M Sobrinho-Simões
Journal:  Gastroenterology       Date:  2001-10       Impact factor: 22.682

View more
  16 in total

1.  Combined effect of miR-146a rs2910164 G/C polymorphism and Toll-like receptor 4 +3725 G/C polymorphism on the risk of severe gastric atrophy in Japanese.

Authors:  Asahi Hishida; Keitaro Matsuo; Yasuyuki Goto; Mariko Naito; Kenji Wakai; Kazuo Tajima; Nobuyuki Hamajima
Journal:  Dig Dis Sci       Date:  2010-08-19       Impact factor: 3.199

Review 2.  New insights into the inactivation of gastric tumor suppressor RUNX3: the role of H. pylori infection.

Authors:  Ying-Hung Nicole Tsang; Acacia Lamb; Lin-Feng Chen
Journal:  J Cell Biochem       Date:  2011-02       Impact factor: 4.429

3.  Immunoexpression of cyclooxygenase-2 in primary gastric carcinomas and lymph node metastases.

Authors:  Paulo R C Almeida; Francisco V A Ferreira; Cássio C Santos; Francisco D Rocha-Filho; Raul R R P Feitosa; Esther A A Falcão; Belise K Cavada; Roberto C P Lima-Júnior; Ronaldo A Ribeiro
Journal:  World J Gastroenterol       Date:  2012-02-28       Impact factor: 5.742

Review 4.  Endoscopic surveillance strategy after endoscopic resection for early gastric cancer.

Authors:  Tsutomu Nishida; Masahiko Tsujii; Motohiko Kato; Yoshito Hayashi; Tomofumi Akasaka; Hideki Iijima; Tetsuo Takehara
Journal:  World J Gastrointest Pathophysiol       Date:  2014-05-15

5.  Leukotriene B4-receptor-1 mediated host response shapes gut microbiota and controls colon tumor progression.

Authors:  Venkatakrishna R Jala; Paramahamsa Maturu; Sobha R Bodduluri; Elangovan Krishnan; Steven Mathis; Krishnaprasad Subbarao; Min Wang; Alfred B Jenson; Mary L Proctor; Eric C Rouchka; Rob Knight; Bodduluri Haribabu
Journal:  Oncoimmunology       Date:  2017-08-10       Impact factor: 8.110

6.  No associations of Toll-like receptor 2 (TLR2) -196 to -174del polymorphism with the risk of Helicobacter pylori seropositivity, gastric atrophy, and gastric cancer in Japanese.

Authors:  Asahi Hishida; Keitaro Matsuo; Yasuyuki Goto; Mariko Naito; Kenji Wakai; Kazuo Tajima; Nobuyuki Hamajima
Journal:  Gastric Cancer       Date:  2010-12-03       Impact factor: 7.370

Review 7.  Hematologic manifestations of Helicobacter pylori infection.

Authors:  Germán Campuzano-Maya
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 8.  Epigenetics: connecting environment and genotype to phenotype and disease.

Authors:  S P Barros; S Offenbacher
Journal:  J Dent Res       Date:  2009-05       Impact factor: 6.116

9.  Short-term celecoxib intervention is a safe and effective chemopreventive for gastric carcinogenesis based on a Mongolian gerbil model.

Authors:  Chao-Hung Kuo; Huang-Ming Hu; Pei-Yun Tsai; I-Chen Wu; Sheau-Fang Yang; Lin-Li Chang; Jaw-Yuan Wang; Chang-Ming Jan; Wen-Ming Wang; Deng-Chyang Wu
Journal:  World J Gastroenterol       Date:  2009-10-21       Impact factor: 5.742

10.  NAT2 polymorphism in Omani gastric cancer patients-risk predisposition and clinicopathological associations.

Authors:  Mansour S Al-Moundhri; Mohamed Al-Kindi; Maryam Al-Nabhani; Bassim Al-Bahrani; Ikram A Burney; Ali Al-Madhani; Shyam S Ganguly; Misbah Tanira
Journal:  World J Gastroenterol       Date:  2007-05-21       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.